TIDMMXC
RNS Number : 6092R
MGC Pharmaceuticals Limited
09 March 2021
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX become
ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited
ABN 30 116 800 269
We (the entity) give ASX the following information under listing
rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director Stephen Barry Parker
Date of last notice 13 March 2019
----------------------------------
Part 1 - Change of director's relevant interests in
securities
In the case of a trust, this includes interests in the trust
made available by the responsible entity of the trust
Note: In the case of a company, interests which come within
paragraph (i) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Direct or indirect Indirect
interest
Nature of indirect Held through a UK Individual Savings
interest Account ("ISA")
(including registered
holder) Registered Holder is Barclays Bank PLC
Note: Provide details
of the circumstances
giving rise to the
relevant interest.
----------------------------------------
Date of change 5 March 2021
----------------------------------------
No. of securities held Nil
prior to change
----------------------------------------
Class Ordinary shares
----------------------------------------
Number acquired 282,316
----------------------------------------
Number disposed -
----------------------------------------
Value/Consideration GBP 9,999.99
Note: If consideration
is non-cash, provide
details and estimated
valuation
----------------------------------------
No. of securities held 282,316 ordinary shares
after change
----------------------------------------
Nature of change On-market trade
Example: on-market
trade, off-market trade,
exercise of options,
issue of securities
under dividend reinvestment
plan, participation
in buy-back
----------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within
paragraph (ii) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Detail of contract N/A
Nature of interest
----
Name of registered holder
(if issued securities)
----
Date of change
----
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
----
Interest acquired
----
Interest disposed
----
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated valuation
----
Interest after change
----
Part 3 - + Closed period
Were the interests in the securities No
or contracts detailed above traded
during a + closed period where prior
written clearance was required?
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
---
If prior written clearance was provided,
on what date was this provided?
---
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX become
ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited
ABN 30 116 800 269
We (the entity) give ASX the following information under listing
rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director Brett Anthony Mitchell
Date of last notice 12 August 2020
------------------------------------
Part 1 - Change of director's relevant interests in
securities
In the case of a trust, this includes interests in the trust
made available by the responsible entity of the trust
Note: In the case of a company, interests which come within
paragraph (i) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Direct or indirect Indirect
interest
Nature of indirect Brett and Michelle Mitchell <Mitchell
interest Spring Family A/C>
(including registered Trustee
holder) Brett and Michelle Mitchell <Lefthanders
Note: Provide details Super Fund A/C>
of the circumstances Trustee
giving rise to the
relevant interest.
-------------------------------------------------------
Date of change 5 March 2021
-------------------------------------------------------
No. of securities held Brett and Michelle Mitchell <Mitchell
prior to change Spring Family A/C>
22,264,444 Fully Paid Ordinary Shares
3,750,000 Performance Rights
277,777 Listed Options exercisable at
$0.045 each expiring 31 August 2021
Brett and Michelle Mitchell <Lefthanders
Super Fund A/C>
8,140,560 Fully Paid Ordinary Shares
3,750,000 Performance Rights
277,777 Listed Options exercisable at
$0.045 each expiring 31 August 2021
Chieftain Securities Pty Ltd
5,000,000 Unlisted Options exercisable
at $0.15 expiring 30 June 2021
1,500,000 Unlisted Options exercisable
at $0.05 expiring 31 August 2023
1,500,000 Unlisted Options exercisable
at $0.06 expiring 31 August 2023
1,500,000 Unlisted Options exercisable
at $0.07 expiring 31 August 2023
-------------------------------------------------------
Class Performance Rights
-------------------------------------------------------
Number acquired Nil
-------------------------------------------------------
Number disposed 2,500,000
-------------------------------------------------------
Value/Consideration Nil - Cancellation of performance rights
Note: If consideration
is non-cash, provide
details and estimated
valuation
-------------------------------------------------------
No. of securities held Brett and Michelle Mitchell <Mitchell
after change Spring Family A/C>
22,264,444 Fully Paid Ordinary Shares
2,500,000 Performance Rights
277,777 Listed Options exercisable at
$0.045 each expiring 31 August 2021
Brett and Michelle Mitchell <Lefthanders
Super Fund A/C>
8,140,560 Fully Paid Ordinary Shares
2,500,000 Performance Rights
277,777 Listed Options exercisable at
$0.045 each expiring 31 August 2021
Chieftain Securities Pty Ltd
5,000,000 Unlisted Options exercisable
at $0.15 expiring 30 June 2021
1,500,000 Unlisted Options exercisable
at $0.05 expiring 31 August 2023
1,500,000 Unlisted Options exercisable
at $0.06 expiring 31 August 2023
1,500,000 Unlisted Options exercisable
at $0.07 expiring 31 August 2023
-------------------------------------------------------
Nature of change Cancellation of performance shares due
Example: on-market to performance conditions lapsing.
trade, off-market trade,
exercise of options,
issue of securities
under dividend reinvestment
plan, participation
in buy-back
-------------------------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within
paragraph (ii) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Detail of contract N/A
Nature of interest
----
Name of registered holder
(if issued securities)
----
Date of change
----
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
----
Interest acquired
----
Interest disposed
----
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated valuation
----
Interest after change
----
Part 3 - + Closed period
Were the interests in the securities No
or contracts detailed above traded
during a + closed period where prior
written clearance was required?
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
---
If prior written clearance was provided,
on what date was this provided?
---
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX
as soon as available. Information and documents given to ASX become
ASX's property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity MGC Pharmaceuticals Limited
ABN 30 116 800 269
We (the entity) give ASX the following information under listing
rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.
Name of Director Roby Reuven Zomer
Date of last notice 12 August 2020
-------------------------------
Part 1 - Change of director's relevant interests in
securities
In the case of a trust, this includes interests in the trust
made available by the responsible entity of the trust
Note: In the case of a company, interests which come within
paragraph (i) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Direct or indirect interest Indirect
Nature of indirect interest Chitta Lu Limited (Director
(including registered holder) and sole shareholder)
Note: Provide details of the
circumstances giving rise to
the relevant interest.
--------------------------------------------------
Date of change 5 March 2021
--------------------------------------------------
No. of securities held prior Chitta Lu Limited
to change 3,000,001 Fully Paid Ordinary
Shares
7,500,000 Performance Rights
HSBC Custody Nominees (Australia)
Limited
30,000,000 Fully Paid Ordinary
Shares
--------------------------------------------------
Class Performance Rights
--------------------------------------------------
Number acquired Nil
--------------------------------------------------
Number disposed 2,500,000 Performance Rights
--------------------------------------------------
Value/Consideration Non-cash - forfeited due to
Note: If consideration is non-cash, not meeting performance conditions.
provide details and estimated
valuation
--------------------------------------------------
No. of securities held after Chitta Lu Limited
change 3,000,001 Fully Paid Ordinary
Shares
5,000,000 Performance Rights
HSBC Custody Nominees (Australia)
Limited
30,000,000 Fully Paid Ordinary
Shares
--------------------------------------------------
Nature of change Cancellation of performance
Example: on-market trade, off-market rights due to performance
trade, exercise of options, conditions lapsing
issue of securities under dividend
reinvestment plan, participation
in buy-back
--------------------------------------------------
Part 2 - Change of director's interests in contracts
Note: In the case of a company, interests which come within
paragraph (ii) of the definition of "notifiable interest of a
director" should be disclosed in this part.
Detail of contract N/A
Nature of interest
----
Name of registered holder
(if issued securities)
----
Date of change
----
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
----
Interest acquired
----
Interest disposed
----
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated valuation
----
Interest after change
----
Part 3 - + Closed period
Were the interests in the securities N/A
or contracts detailed above traded
during a + closed period where prior
written clearance was required?
If so, was prior written clearance
provided to allow the trade to proceed
during this period?
----
If prior written clearance was provided,
on what date was this provided?
----
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGLGDXIXGDGBC
(END) Dow Jones Newswires
March 09, 2021 02:00 ET (07:00 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Dec 2023 to Dec 2024
